
On the heеls of the previous post, here is another news bit on the topic of retinal implants. Over the years, we have witnessed a variety of approaches being applied for retinal stimulation, including the epiretinal, subretinal, and suprachoroidal. One feature, however, remained unchanged in those varied types of implants – a planar geometry of the stimulation array. At least until now. As the competition in the retinal implant sector is heating up, the issues of low-power operation and improved electrode contact with retinal neurons is fueling the development of stimulation arrays featuring the 3D geometries. Improved charge delivery to retinal neurons has been achieved a few years ago by fabricating the protruding 3D nanoelectrodes in Daniel Palanker’s lab at Stanford University and at Dong-Il Dan Cho’s and Sung June Kim’s labs at Seoul National University. Now, preparing to reach even deeper into the retina, the Israeli company Nano-Retina Inc., co-founded by Rainbow Medical Ltd. and Zyvex Labs. , is developing the Bio-Retina implant featuring the array of 100-µm-sized penetrating electrodes. Their length should allow the electrodes to reach the layer of bipolar cells that are spared in AMD and other degenerating retinal disorders. The first-generation array will have 24×24 electrodes and the second – 72×72. Power to the device will be delivered wirelessly using the infrared light beamed from the glasses. To expedite their efforts in developing the low-power IC chip with the built-in photodetector array and power telemetry, Nano-Retina has teamed up with CMES (Centre Suisse d’Electronique et de Microtechnique), a non-profit R&D center in Switzerland. According to their (perhaps too optimistic) estimates they plan to have the functional device ready for clinical trials by 2013 and even have estimated the target price of $60K for the Bio-Retina implant. We wish the best of luck to this young ambitious company, hoping it has what it takes to develop a device from scratch in such a short period of time.



The fear is one of the strongest emotions that drive our behavior. And the amygdala is the central hub for processing the fear responses. How would our life be changed if we were to lose both of the amygdalae? While the animals can be deprived of fear by knocking out Stathmin, a cytoskeleton regulatory protein concentrated in the amygdala and other parts of the fear circuit, these animals cannot report on their internal subjective experience. Unfortunately, no drug is presently safe enough for a temporary amygdala inactivation in humans. Our understanding of a human condition without the amygdalae has been, therefore, rather limited, relying on a handful of patients with a rare genetic disorder, 
Rechargeable batteries are increasingly more common in neural implants, removing the need for multiple surgeries to replace a depleted battery. Alternative strategies are being developed for replenishing the energy of the battery. The most established method of energy delivery is via radio waves. Recent shift toward the use of higher frequencies in the 0.1-1 GHz band made the rectenna (receiving antenna) extremely small. This allowed the implant to fit within an injectable needle for a minimally invasive delivery at a location near a peripheral nerve. In order to eliminate the need for coupling the implant with an external charging device, methods are being developed for harvesting the energy from the human body. These methods utilize the energy of light (visible or infrared), heat, or vibration. Harvesting of visible light can be done most efficiently in the
Chemical stimulation using channels in a so-called “puffer” neural probe has been a challenging endeavor, originated by Prof. Kendal Wise’s laboratory in U. Michigan back in 

A remarkable milestone has been reached in the resolution of retinal implants – a whopping 1520 pixels (38×40)! Following on the heels of a recent success of Argus II retinal implants developed by the
Cochlear implants have been around for decades restoring hearing in profoundly deaf people. Now, with the help 
Centre for the Mind at the University of Sydney NSW, directed by
Development of new neurotechnologies is driven by a paramount goal of restoring neural functions. Presently, no commercial companies or government-funded research laboratories are actively pursuing the technologies aiming at augmenting and enhancing the functions of the brain or spinal cord in able-bodied humans. Yet, such technologies can readily be developed with minimal modifications of the existing neuro-restorative technologies. Let’s consider, for example the retinal implants (e.g. from